This story has been updated.
SAN FRANCISCO — At his initial news discussion as president-elect on Wednesday, Donald Trump indicted a curative attention of “getting divided with murder” and pronounced that he would change a approach a nation bids on drugs to move prices and spending down.
“Pharma has a lot of lobbies, a lot of lobbyists and a lot of power. And there’s really small behest on drugs,” Trump pronounced during a eventuality during Trump Tower in New York. “We’re a largest customer of drugs in a world, and nonetheless we don’t bid properly.”
Federal law forbids a supervision from negotiating with drug companies to move down a cost of drugs for seniors regulating Medicare. While Trump did not announce a specific devise to residence a issue, he has in a past called for finale a process — a offer that Democratic lawmakers have regularly put forward.
The critique forsaken a explosve into a center of a drug industry’s vital annual financier discussion underway in San Francisco this week, promulgation curative and biotech bonds plunging. The iShares NASDAQ Biotechnology Index sealed down 3 percent Wednesday.
Speaking during a JP Morgan Healthcare Conference, Mylan Pharmaceuticals arch executive Heather Bresch, who has been underneath inspection for her company’s steady list cost increases on a lifesaving allergy drug EpiPen, pronounced that it would be “premature” to respond to a president-elect’s comments since his specific skeleton are unknown. But she pronounced a flourishing open cheer over a cost of drugs has assured her that a complement contingency change.
“If anybody is walking divided from this discussion meditative ‘business as usual,’ we consider that’s a mistake,” Bresch said. “The pricing indication has got to change. It’s not incremental change; we don’t consider that’s what this nation needs. we consider it’s truly rethinking a business model.”
Pharmaceutical association AbbVie announced during a discussion that it would rage a drug prices to single-digit increases annually, following identical announcements from Allergan and Novo Nordisk in new months.
The proclamation was separate to Trump’s comments, that came as a association was giving a display during a conference. Chief executive Richard Gonzalez pronounced he had small discernment into what Trump’s critique would meant for a industry.
“I don’t have a clear round as to what changes a boss has in mind,” he said.
In a phone interview, Allergan arch executive Brent Saunders forked out that, in many respects, a approaching pro-business bulletin underneath Trump and a Republican Congress — such as corporate taxation remodel — will advantage a industry. But open annoy about drug prices stays a vulnerability, he added.
Saunders has been outspoken that drug companies should uncover patience in pricing to equivocate a supervision involvement that could suppress a industry.
“Unfortunately, this is what we was disturbed about,” Saunders said. “It’s a finish counterbalance to contend a attention is removing divided with murder when a attention is committed to saving and improving lives.”
He pronounced Trump’s comments could have inclusive implications, scaring investors divided from a health caring space.
“It goes to uncover a sentiment, and that causes investors that aren’t health-care specialists pause, in terms of investing in health care,” Saunders said. “It could means investors in try collateral to have postponement in putting income prolonged tenure into health care, and it could suppress innovation.”
Rep. Peter Welch (D-Vt.) introduced a check final week that would concede for Medicare negotiation. A 2007 Congressional Budget Office research found that a ability to negotiate alone for Medicare’s medication drug advantage could be sincerely toothless, carrying a “negligible outcome on Medicare drug spending” though a ability to set prices or bar drugs from coverage altogether by formulating a formulary.
After Trump’s vicious comments on a curative industry, Sen. Bernie Sanders (I-Vt.) tweeted his agreement.
Trump is right: pharma is “getting divided with murder.” But do Trump and Republicans have a courage to military drug companies and reduce prices?
— Bernie Sanders (@SenSanders) January 11, 2017
Trump also criticized drug companies for “leaving left and right,” potentially a anxiety to “tax inversions,” in that companies combine with unfamiliar companies to immigrate their domicile in countries with some-more auspicious taxation rates. And he denounced a companies for production their products abroad.
Ronny Gal, an researcher with Sanford C. Bernstein and Co., pronounced that many drug manufacturers have been gradually relocating production overseas, quite general manufacturing.
Several arch executives pronounced they would acquire a possibility to boost production in a United States, if a business and taxation meridian were some-more auspicious — something that many wish will change underneath Trump.
Regeneron arch executive Leonard Schleifer pronounced a largest production ability is in a U.S., yet a association also has a plant in Ireland.
“There’s copiousness of production that does go offshore, though drugs are also sole offshore,” Schleifer said. “The mercantile and taxation policies are going to make a disproportion here.”
More from Wonkblog: